These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 1539195)

  • 1. Treatment of erectile impotence in renal transplant patients with intracavernosal vasoactive drugs.
    Rodriguez Antolin A; Morales JM; Andrés A; Fernández Aparicio T; Díaz González R; Pamplona M; Alvarez E
    Transplant Proc; 1992 Feb; 24(1):105-6. PubMed ID: 1539195
    [No Abstract]   [Full Text] [Related]  

  • 2. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
    Purvis K; Brekke I; Christiansen E
    Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracavernosal injection of pharmacological agents in the diagnosis and treatment of impotence.
    Siraj QH; Akhtar MA
    J Pak Med Assoc; 1989 Jul; 39(7):172-6. PubMed ID: 2504962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
    Vardi Y; Lidgi S; Moskovitz B; Levin RD
    Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
    Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
    Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Our experience with pharmacological erection treatment of erectile dysfunction.
    Hattat H; Ozkara H; Akkus E; Alici B
    J Androl; 1994; 15 Suppl():47S-49S. PubMed ID: 7721677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of vasoactive agents in the treatment of erectile impotence.
    Fried FA
    N C Med J; 1990 Jun; 51(6):295-6. PubMed ID: 2366889
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction.
    Perimenis P; Konstantinopoulos A; Perimeni PP; Gyftopoulos K; Kartsanis G; Liatsikos E; Athanasopoulos A
    Asian J Androl; 2006 Mar; 8(2):219-24. PubMed ID: 16491275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of erectile responses to vasoactive drugs by a variable amplitude oscillation device.
    Chun SS; Fenemore J; Heaton JP; Johnston B; Morales A
    Int J Impot Res; 1996 Dec; 8(4):221-5. PubMed ID: 8981171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].
    Hayashi S; Iwai Y; Yasumoto R; Matsuda J; Kawano M; Omachi T; Kono T; Yamamoto S; Sakakura T; Minami H
    Hinyokika Kiyo; 1994 Jan; 40(1):37-41. PubMed ID: 7509119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical study of male sexual activity on chronic hemodialysis after renal transplantation.
    Ishii T; Nagano T; Hara Y; Negita M; Nishioka T; Akiyama T; Kurita T
    Transplant Proc; 1996 Jun; 28(3):1646-8. PubMed ID: 8658820
    [No Abstract]   [Full Text] [Related]  

  • 14. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
    Asuar Aydillo S
    Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of intracavernosal injection of papaverine hydrochloride on orgasm latency.
    Levitt EE; Mulcahy JJ
    J Sex Marital Ther; 1995; 21(1):39-41. PubMed ID: 7608997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E1 in the treatment of impotence.
    Sarosdy MF; Hudnall CH; Erickson DR; Hardin TC; Novicki DE
    J Urol; 1989 Mar; 141(3):551-3. PubMed ID: 2645420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experience in the treatment of erectile impotence by the intracavernous auto-injection of vasoactive substances].
    Ferrière JM; Gaston R; Piechaud T; Le Guillou M
    Ann Urol (Paris); 1988; 22(1):57-9. PubMed ID: 3369847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin E1 therapy for impotence, comparison with papaverine.
    Earle CM; Keogh EJ; Wisniewski ZS; Tulloch AG; Lord DJ; Watters GR; Glatthaar C
    J Urol; 1990 Jan; 143(1):57-9. PubMed ID: 2294263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intracavernosa injections of drugs in erection disorders. Their clinical value apropos of 100 cases].
    Bondil P; Rigot JM; Nguyen Qui JL; Mazeman E
    J Urol (Paris); 1987; 93(9-10):547-8. PubMed ID: 3443767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury.
    Earle CM; Keogh EJ; Ker JK; Cherry DJ; Tulloch AG; Lord DJ
    Paraplegia; 1992 Apr; 30(4):273-6. PubMed ID: 1625897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.